Developed and validated script for 18F – PSMA -1007 Synthesis in IBA – Synthera version-01

Abstract

Prostate cancer is the most frequent cancer among males around the world. According to the American Cancer Society's website, one out of every nine males is likely to be diagnosed with prostate cancer [1]. It is the world's second greatest cause of death among males. PSA, or prostate-specific antigen, is a popular biomarker for prostate cancer. For early disease detection, standard imaging technologies such as CT and MRI have not proved sufficient information. PET imaging in conjunction with CT/MRI is a useful tool for detecting prostate cancer [2]. PSMA (prostate-specific membrane antigen) tagged with radioisotopes is a promising agent for both early detection and therapy of prostate cancer. In prostate cancer cells, PSMA is overexpressed. As a service provider, we decided to create and supply the 18F-PSMA 1007 in response to the clinical need for PSMA in nuclear medicine departments. We've been commercially generating 18F-FDG and 18F NaF since 2009, and we thought 18F-PSMA was a tracer with clinical potential as well as economic potential and added value to the company. Despite the fact that we had already purchased a synthesiser (Trasis AllInOne) capable of producing 18F-PSMA-1007, installation and commissioning were nowhere to be found. As a result, we used Synthera v1 to make 18F-PSMA-1007 (Synthera v1; already retired by IBA, the manufacturer). Regent kits to make 18F-PSMA-1007 with more recent versions of Synthera (Synthera v2 and Synthera Plus) were available, and the product may be used in our experiments, but there was no approved synthesis script / sequence for Synthera v1. As a result, the first task was to write the /sequence script.